Durata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012
October 04 2012 - 7:45AM
Business Wire
Durata Therapeutics (NASDAQ: DRTX) today announced that data
from two clinical trials of its lead product candidate,
dalbavancin, will be presented in two posters during the IDWeek
conference in San Diego from October 17-21, 2012.
IDWeek is the first-ever combined meeting of four prestigious
societies: the Infectious Diseases Society of America (IDSA), the
Society for Healthcare Epidemiology of America (SHEA), the HIV
Medicine Association (HIVMA), and the Pediatric Infectious Diseases
Society (PIDS).
Durata is presenting the data during the Novel Antimicrobial
Agents session on Saturday, October 20, 12:30 – 2:00 p.m. PT in
Halls F-H:
- A Study to Assess Skin Lesion
Measurement Techniques Related to Acute Bacterial Skin and Skin
Structure Infections (Dunne, et al). Abstract Number: 36757.
Presenting author: Michael Dunne, MD
- The effect of lung surfactant on the in
vitro activity of dalbavancin against Staphylococcus aureus and
Streptococcus pneumoniae (Dunne, et al). Abstract Number: 36184.
Presenting authors: Michael Dunne, MD and Laura Koeth
Durata will display the two posters from Thursday, October 18 at
9:30 a.m. until Saturday, October 20 at 6:00 p.m.
About Dalbavancin
Dalbavancin is an intravenous antibiotic product candidate under
investigation for once-weekly dosing, which we believe may
facilitate the treatment of patients with ABSSSI in both the
in-patient and out-patient settings, potentially reducing the
length of a patient’s hospital stay or avoiding hospital admission
altogether, with an impact on the overall cost of care for these
patients.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for
patients with infectious diseases and acute illnesses. Durata is
currently enrolling and dosing patients in two global Phase 3
clinical trials with its lead product candidate, dalbavancin, for
the treatment of patients with acute bacterial skin and skin
structure infections, or ABSSSI.
Forward-looking statements
Any statements in this press release about Durata’s future
expectations, plans and prospects constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will
cause its views to change. However, while Durata may elect to
update these forward-looking statements at some point in the
future, Durata specifically disclaims any obligation to do so.
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024